Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Genelux Corp (GNLX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.82-7.14%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GNLX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce losses and improve EPS | A primary condition in Genelux Corp's published investment case. The stated target is EPS loss improves to about -$0.76 in FY27. | Intact | EPS loss worsens beyond -$0.8 in FY27 | Diluted EPS: $-0.21 per share FY2026-Q2; GAAP. Published target: EPS loss improves to about -$0.76 in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-0.21 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established compounder. The long-term thesis is in a watch state: performance trails its industry cohort, and the evidence snapshot has low overall confidence.
The valuation evidence flags GNLX as expensive, but says the market is not pricing in the full combination of expensive valuation, weak results, and turbulent conditions. The evidence does not provide enough detail to judge how much recovery or future growth is assumed.
Recent financial performance is weak and well below the industry cohort, while earnings remain loss-making. Near term, the next report carries elevated miss risk for a smaller company in a high-miss-rate industry; the snapshot does not provide specific operating forecasts.
Over the next few quarters, a weakening jobs trend could increase recession concerns and weigh on cyclical businesses. The multi-year view also hinges on whether Healthcare leaders continue to report strong results and guidance, supporting the sector backdrop, or begin to weaken and remove that support.
The 1-to-3-year read is cautious: GNLX combines weak, loss-making fundamentals with high risk, while sector momentum is a possible support rather than a company-specific proof point. The evidence is thin and low confidence, so the thesis remains watchful. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain sufficient funding for clinical trials |
| Debt issuances provide funding to support ongoing trials. |
| Intact |
| Company unable to secure funding or forced to dilute significantly |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve initial revenue from clinical-stage products | A primary condition in Genelux Corp's published investment case. The stated target is >= $12 million revenue in FY27. | Intact | revenue fails to reach $12 million in FY27 | Revenue: $0 FY2026-Q2; GAAP. Published target: >= $12 million revenue in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20260 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.76 → $-0.75 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-07-25 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-07-26 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-07-27 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-07-28 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-07-29 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-07-30 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-07-31 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-08-01 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-02 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-03 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-04 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-05 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-08-06 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-07 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-08 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-08-09 | $-0.76 | $12,182,000 | 5 / 6 |
| 2026-08-10 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-12 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-13 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-14 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-15 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-16 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-17 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-18 | $-0.76 | $12,182,000 | 3 / 4 |
| 2026-08-19 | $-0.76 | $12,182,000 | 4 / 4 |
| 2026-08-20 | $-0.72 | $12,182,000 | 4 / 3 |
| 2026-08-21 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-22 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-23 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-24 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-25 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-26 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-27 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-28 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-29 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-30 | $-0.72 | $12,182,000 | 4 / 4 |
| 2026-08-31 | $-0.74 | $8,138,400 | 4 / 4 |
| 2026-09-01 | $-0.74 | $8,138,400 | 4 / 4 |
| 2026-09-02 | $-0.74 | $8,138,400 | 4 / 4 |
| 2026-09-03 | $-0.74 | $8,138,400 | 4 / 4 |
| 2026-09-04 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-05 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-06 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-07 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-08 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-09 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-10 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-11 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-12 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-13 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-14 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-15 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-16 | $-0.74 | $8,138,400 | 3 / 3 |
| 2026-09-17 | $-0.75 | $7,848,667 | 3 / 3 |
| 2026-09-18 | $-0.75 | $7,848,667 | 3 / 3 |
| 2026-09-19 | $-0.75 | $7,848,667 | 3 / 3 |
| 2026-09-20 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-21 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-22 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-23 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-24 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-25 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-26 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-27 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-28 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-29 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-09-30 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-01 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-02 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-03 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-04 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-05 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-06 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-07 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-08 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-09 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-10 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-11 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-12 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-13 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-14 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-15 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-16 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-17 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-18 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-19 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-20 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-21 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-22 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-23 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-24 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-25 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-26 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-27 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-28 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-29 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-30 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-10-31 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-11-01 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-11-02 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-11-03 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-11-04 | $-0.75 | $7,848,667 | 4 / 4 |
| 2026-11-05 | $-0.75 | $7,848,667 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.